PremiumRatingsPromising Potential and Financial Stability Drive Buy Rating for 4D Molecular Therapeutics Promising Advancements in 4D Molecular Therapeutics’ Gene Therapy Programs Drive Buy Rating 4D Molecular price target lowered to $38 from $45 at Barclays PremiumThe Fly4D Molecular announces RMAT designation granted by FDA for 4D-150 for DME Biotech stocks slide as Marks resignation seen being negative for sector BMO says Peter Marks resignation ‘significant negative’ for biotech PremiumRatingsPromising Developments in 4D Molecular Therapeutics’ Gene Therapy Program Justify Buy Rating 4D Molecular Therapeutics Reports Strong Clinical Progress and Financial Position Optimistic Buy Rating for 4D-150 Driven by PRISM Study’s Promising Results in Treating Wet Age-Related Macular Degeneration